The stock of NuVasive, Inc. (NASDAQ:NUVA) reached all time high today, Oct, 10 and still has $94.68 target or 37.00% above today’s $69.11 share price. This indicates more upside for the $3.48 billion company. This technical setup was reported by Barchart.com. If the $94.68 PT is reached, the company will be worth $1.29B more.
Trading stocks at an all time highs is usually a winning strategy. An all time high points to a stock which has the most positive fundamentals ever. Even thought the pullback rate is high, if correct risk management is utilized, investors can trade very well such events. About 324,157 shares traded hands. NuVasive, Inc. (NASDAQ:NUVA) has risen 53.48% since March 7, 2016 and is uptrending. It has outperformed by 45.89% the S&P500.
Analysts await NuVasive, Inc. (NASDAQ:NUVA) to report earnings on October, 25. They expect $0.40 earnings per share, up 14.29% or $0.05 from last year’s $0.35 per share. NUVA’s profit will be $20.14M for 43.19 P/E if the $0.40 EPS becomes a reality. After $0.40 actual earnings per share reported by NuVasive, Inc. for the previous quarter, Wall Street now forecasts 0.00% EPS growth.
NuVasive, Inc. (NASDAQ:NUVA) Ratings Coverage
Out of 13 analysts covering Nuvasive Inc. (NASDAQ:NUVA), 11 rate it a “Buy”, 0 “Sell”, while 2 “Hold”. This means 85% are positive. Nuvasive Inc. has been the topic of 19 analyst reports since July 29, 2015 according to StockzIntelligence Inc. Northland Capital upgraded NuVasive, Inc. (NASDAQ:NUVA) on Thursday, July 30 to “Outperform” rating. The company was upgraded on Wednesday, July 13 by JP Morgan. The firm has “Buy” rating by Leerink Swann given on Tuesday, September 1. Jefferies maintained NuVasive, Inc. (NASDAQ:NUVA) on Wednesday, July 27 with “Buy” rating. Barclays Capital maintained NuVasive, Inc. (NASDAQ:NUVA) rating on Wednesday, July 27. Barclays Capital has “Overweight” rating and $71 price target. Canaccord Genuity upgraded it to “Buy” rating and $58 target price in Tuesday, October 6 report. On Monday, September 14 the stock rating was initiated by Morgan Stanley with “Equal-Weight”. As per Wednesday, April 27, the company rating was maintained by Cowen & Co. The rating was upgraded by Bank of America on Friday, December 11 to “Neutral”. UBS initiated the shares of NUVA in a report on Tuesday, September 22 with “Buy” rating.
According to Zacks Investment Research, “NUVASIVE is a medical device company focused on the design, development and marketing of products for the surgical treatment of spine disorders. The Company’s product portfolio is focused on applications in the over $4.2 billion U.S. spine fusion market. The Company’s current principal product offering includes a minimally disruptive surgical platform called Maximum Access Surgery, or MAS, as well as a growing offering of cervical and motion preservation products.”
Insitutional Activity: The institutional sentiment decreased to 1.11 in Q2 2016. Its down 0.06, from 1.17 in 2016Q1. The ratio dived, as 37 funds sold all NuVasive, Inc. shares owned while 77 reduced positions. 45 funds bought stakes while 82 increased positions. They now own 50.84 million shares or 1.81% more from 49.94 million shares in 2016Q1.
Blackrock Limited Liability Company holds 0.03% of its portfolio in NuVasive, Inc. (NASDAQ:NUVA) for 508,351 shares. Bank Of New York Mellon Corp, a New York-based fund reported 596,525 shares. The Illinois-based Castleark Limited Company has invested 0.38% in NuVasive, Inc. (NASDAQ:NUVA). Cibc World Markets holds 0.58% or 372,202 shares in its portfolio. The California-based Blackrock Institutional Trust Na has invested 0.01% in NuVasive, Inc. (NASDAQ:NUVA). Tudor Inv Et Al holds 0% or 3,712 shares in its portfolio. Goldman Sachs has invested 0.03% of its portfolio in NuVasive, Inc. (NASDAQ:NUVA). Eagle Asset Mngmt Inc has 981,194 shares for 0.41% of their US portfolio. Tfs Limited Liability Corp holds 0.19% of its portfolio in NuVasive, Inc. (NASDAQ:NUVA) for 17,617 shares. Nicholas Inv Ltd Partnership has 0.16% invested in the company for 37,589 shares. Foundry Prns Ltd Liability Co has 5,975 shares for 0.02% of their US portfolio. Marshall Wace Llp last reported 0.03% of its portfolio in the stock. Gemmer Asset Mgmt Lc last reported 97 shares in the company. Independent Portfolio Consultants holds 0.02% of its portfolio in NuVasive, Inc. (NASDAQ:NUVA) for 1,290 shares. Moreover, Stifel Fincl has 0.03% invested in NuVasive, Inc. (NASDAQ:NUVA) for 124,885 shares.
Insider Transactions: Since June 15, 2016, the stock had 0 insider purchases, and 5 insider sales for $2.12 million net activity. Hannon Jason also sold $170,100 worth of NuVasive, Inc. (NASDAQ:NUVA) on Tuesday, August 23. HOWE LESLEY H also sold $224,909 worth of NuVasive, Inc. (NASDAQ:NUVA) shares.
Another recent and important NuVasive, Inc. (NASDAQ:NUVA) news was published by Twst.com which published an article titled: “NuVasive Inc.: NuVasive Announces Conference Call and Webcast of Third Quarter …” on September 26, 2016.
NUVA Company Profile
Nuvasive, Inc., incorporated on July 21, 1997, is a medical device firm in the spine market. The Firm focuses on developing minimally-disruptive surgical products and procedurally-integrated solutions for the spine. The Firm offers two product lines: spine surgery products and biologics. The Company’s spine surgery products line offerings include thoracolumbar product offerings, cervical product offerings, Intra-Operative Monitoring (IOM) services and disposables, which are used to enable access to the spine and to perform restorative and fusion procedures in a minimally disruptive fashion. The Company’s biologics product line offerings includes allograft (donated human tissue), FormaGraft (a collagen synthetic product), Osteocel Plus and Osteocel Pro (each an allograft cellular matrix containing viable mesenchymal stem cells (MSCs)), and AttraX (a synthetic bone graft material), all of which are used to aid the spinal fusion or bone healing process.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.